UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD

Abigail Tebboth,1 Andrew Ternouth,1 Nuria Gonzalez-Rojas2 1Boehringer Ingelheim Ltd., Bracknell, UK; 2Boehringer Ingelheim GmBH, Ingelheim, Germany Objective: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinatio...

Descripció completa

Dades bibliogràfiques

Autors principals:	Tebboth A, Ternouth A, Gonzalez-Rojas N
Format:	Artigo
Idioma:	Inglês
Publicat:	Dove Medical Press 2016-11-01
Col·lecció:	ClinicoEconomics and Outcomes Research
Matèries:	COPD economic cost-effectiveness tiotropium + olodaterol
Accés en línia:	https://www.dovepress.com/uk-specific-cost-effectiveness-of-tiotropium--olodaterol-fixed-dose-co-peer-reviewed-article-CEOR
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!